TRCT
WINT

Tower Research Capital (TRC)’s Windtree Therapeutics Inc WINT Stock Holding History

Tower Research Capital (TRC)’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-664
Closed -$1K – 4535
2016
Q4 		$1K Buy
664
+244
+58% +$451 ﹤0.01% 3743
2016
Q3 		$1K Sell
420
-30
-7% -$65 ﹤0.01% 3495
2016
Q2 		$1K Sell
450
-2,047
-82% -$4.95K ﹤0.01% 4323
2016
Q1 		$4K Buy
2,497
+2,211
+773% +$4.75K ﹤0.01% 2999
2015
Q4 		$1K Buy
+286
New +$1.17K ﹤0.01% 4303
2015
Q1 		– Sell
-49
Closed -$1K – 5298
2014
Q4 		$1K Buy
49
+18
+58% +$396 ﹤0.01% 3842
2014
Q3 		$1K Sell
31
-178
-85% -$4.3K ﹤0.01% 4255
2014
Q2 		$5K Buy
+209
New +$5.34K ﹤0.01% 2919
2013
Q4 		– Sell
-156
Closed -$4K – 5218
2013
Q3 		$4K Sell
156
-660
-81% -$16K ﹤0.01% 3864
2013
Q2 		$17K Buy
+816
New +$20.1K ﹤0.01% 1898

Other funds holding WINT

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Tower Research Capital (TRC)'s WINT Position: Q1 2017 in Review

Tower Research Capital (TRC) sold out of Windtree Therapeutics Inc (WINT) in Q1 2017, closing a stake of 664 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in WINT in Q2 2013 and held it in 10 quarters. The position peaked at $17K in Q2 2013. 26 funds tracked by Wall St. Rank hold WINT as of Q1 2017.

  • Tower Research Capital (TRC) reported no remaining Windtree Therapeutics Inc position as of Q1 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 664 Windtree Therapeutics Inc shares in Q1 2017, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in Windtree Therapeutics Inc in Q2 2013 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Windtree Therapeutics Inc position peaked at $17K in Q2 2013.
  • 26 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q1 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.